5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity
Demethylating agent, 5-Azacytidine (5-Aza), has been shown to be active in treatment of myeloid malignancies. 5-Aza enhances anticancer immunity, by increasing expression of tumor-associated antigens. However, the impact of 5-Aza immune responses remains poorly understood. Here, T-cell mediated tumo...
Saved in:
Main Authors: | Thomas Stübig (Author), Anita Badbaran (Author), Tim Luetkens (Author), York Hildebrandt (Author), Djordje Atanackovic (Author), Thomas M. C. Binder (Author), Boris Fehse (Author), Nicolaus Kröger (Author) |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2014-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comment on "5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity"
by: Thomas Mørch Frøsig, et al.
Published: (2015) -
A Perspective on the Comparative Antileukemic Activity of 5-Aza-2'-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)
by: Richard L. Momparler
Published: (2012) -
Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation
by: Adrin Dadkhah, et al.
Published: (2022) -
Elotuzumab as a novel anti-myeloma immunotherapy
by: Sabarinath Venniyil Radhakrishnan, et al.
Published: (2017) -
Steroids in the treatment of acute myeloid leukemia: Antileukemic or leukemogenic?
by: Srishti Srivastava, et al.
Published: (2024)